Head to Head Analysis: Spero Therapeutics (NASDAQ:SPRO) versus Dare Bioscience (NASDAQ:DARE)

Dare Bioscience (NASDAQ:DARE) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, valuation, institutional ownership, profitability and analyst recommendations.

Profitability

This table compares Dare Bioscience and Spero Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Dare Bioscience	-803.80%	-748.30%	-38.75%
Spero Therapeutics	24.90%	16.17%	12.57%

Volatility & Risk

Dare Bioscience has a beta of 1.01, indicating that its share price is 1% more volatile than the S&P 500. Comparatively, Spero Therapeutics has a beta of 1.49, indicating that its share price is 49% more volatile than the S&P 500.

Earnings and Valuation

This table compares Dare Bioscience and Spero Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dare Bioscience	$1.03 million	13.77	-$13.40 million	($0.70)	-1.03
Spero Therapeutics	$66.80 million	1.05	$8.57 million	$0.11	11.00

Spero Therapeutics has higher revenue and earnings than Dare Bioscience. Dare Bioscience is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

6.7% of Dare Bioscience shares are held by institutional investors. Comparatively, 25.6% of Spero Therapeutics shares are held by institutional investors. 4.1% of Dare Bioscience shares are held by insiders. Comparatively, 2.9% of Spero Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and target prices for Dare Bioscience and Spero Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dare Bioscience	1	0	2	0	2.33
Spero Therapeutics	0	2	0	0	2.00

Dare Bioscience currently has a consensus price target of $12.00, suggesting a potential upside of 1,564.36%. Given Dare Bioscience’s stronger consensus rating and higher probable upside, equities analysts plainly believe Dare Bioscience is more favorable than Spero Therapeutics.

Summary

Spero Therapeutics beats Dare Bioscience on 9 of the 14 factors compared between the two stocks.

About Dare Bioscience

Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.

About Spero Therapeutics

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.